ADVERTISEMENT

Psoriatic arthritis: ustekinumab monotherapy suffices

Susan London   |   Clinical Summary   |   13 January 2023
ADVERTISEMENT

The randomised MUST trial suggests no additional benefit on joint signs and symptoms from adding or continuing methotrexate therapy.

Takeaway

  • Ustekinumab monotherapy was noninferior to ustekinumab and methotrexate combination therapy for reducing disease activity in the joints of patients with active psoriatic arthritis.

Why this matters

  • Evidence on the effect...

          

Topic Challenges

left
right